Modulators of protein-protein interactions - novel approaches in targeting protein kinases and other pharmaceutically relevant biomolecules

Current Topics in Medicinal Chemistry

Volumn 11, Issue 11, 2011, Pages 1305-1319

  Rechfeld, Florian ^a   Gruber, Peter ^a   Hofmann, Johann ^a   Kirchmair, Johannes ^b  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b UNIVERSITY OF INNSBRUCK   (Austria)

Author keywords

Molecular modeling; Protein kinases; Protein protein interaction modulators; Protein protein interactions; Rational drug design; Virtual screening

Indexed keywords

AUROTHIOMALATE; BETA CATENIN; CYCLIN A; CYCLIN DEPENDENT KINASE 2; ENFUVIRTIDE; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 41; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MARAVIROC; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; POLO LIKE KINASE 1; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN KINASE; PROTEIN KINASE C; PROTEIN KINASE C EPSILON; PROTEIN KINASE C LAMBDA; PROTEIN MDM2; PROTEIN P300; PROTEIN P53; PROTEIN P56; PROTEIN P62; PROTEIN S100B; SURVIVIN; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR; VICRIVIROC;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CD4+ CD25+ T LYMPHOCYTE; ENZYME ACTIVE SITE; ENZYME STRUCTURE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; NEOPLASM; NONHUMAN; PHYSICAL CHEMISTRY; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; REVIEW; WART VIRUS;

COMPUTATIONAL BIOLOGY; DRUG DESIGN; HUMANS; MOLECULAR DYNAMICS SIMULATION; MOLECULAR TARGETED THERAPY; ORGANIC CHEMICALS; PROTEIN BINDING; PROTEIN KINASE INHIBITORS; PROTEIN KINASES;

EID: 79958143460     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/156802611795589610     Document Type: Review

References (200)

1. Ryan, D.P.; Matthews, J.M. Protein-protein interactions in human disease. Curr. Opin. Struct. Biol., 2005, 15, 441-446.
2. Archakov, A.I.; Govorun, V.M.; Dubanov, A.V.; Ivanov, Y.D.; Veselovsky, A.V.; Lewi, P.; Janssen, P. Protein-protein interactions as a target for drugs in proteomics. Proteomics, 2003, 3, 380-391.
3. Ivanov, A.S.; Gnedenko, O.V.; Molnar, A.A.; Mezentsev, Y.V.; Lisitsa, A.V.; Archakov, A.I. Protein-protein interactions as new targets for drug design: virtual and experimental approaches. J. Bioinform. Comput. Biol., 2007, 5, 579-592.
4. Strong, M.; Eisenberg, D. The protein network as a tool for finding novel drug targets. Prog. Drug. Res., 2007, 64, 193-215.
5. Fry, D.C. Protein-protein interactions as targets for small molecule drug discovery. Biopolymers, 2006, 84, 535-552.
6. Xenarios, L.; Eisenberg, D. Protein interaction databases. Curr. Opin. Biotechnol., 2001, 12, 334-339.
7. Wong, P.; Althammer, S.; Hildebrand, A.; Kirschner, A.; Pagel, P.; Geissler, B.; Smialowski, P.; Blochl, F.; Oesterheld, M.; Schmidt, T.; Strack, N.; Theis, F.J.; Ruepp, A.; Frishman, D. An evolutionary and structural characterization of mammalian protein complex organization. BMC Genomics, 2008, 9, 16.
8. Yin, H.; Hamilton, A.D. Strategies for targeting protein-protein interactions with synthetic agents. Angew. Chem., Int. Ed., 2005, 44, 4130-4163.
9. Wells, J.A.; McClendon, C.L. Reaching for high-hanging fruit in drug discovery at protein-protein interfaces. Nature, 2007, 450, 1001-1009.
10. Arkin, M. Protein-protein interactions and cancer: small molecules going in for the kill. Curr. Opin. Chem. Biol., 2005, 9, 317-324.
11. Arkin, M.R.; Wells, J.A. Small-molecule inhibitors of proteinprotein interactions: progressing towards the dream. Nat. Rev. Drug Discov., 2004, 3, 301-317.
12. Stockwin, L.H.; Holmes, S. Antibodies as therapeutic agents: vive la renaissance! Expert Opin. Biol. Ther., 2003, 3, 1133-1152.
13. Kim, E.S.; Khuri, F.R.; Herbst, R.S. Epidermal growth factor receptor biology (IMC-C225). Curr. Opin. Oncol., 2001, 13, 506-513.
14. Yan, L.; Hsu, K.; Beckman, R.A. Antibody-based therapy for solid tumors. Cancer J., 2008, 14, 178-183.
15. Lichtarge, O.; Sowa, M.E. Evolutionary predictions of binding surfaces and interactions. Curr. Opin. Struct. Biol., 2002, 12, 21-27.
16. Skrabanek, L.; Saini, H.K.; Bader, G.D.; Enright, A.J. Computational prediction of protein-protein interactions. Mol. Biotechnol., 2008, 38, 1-17.
17. Moreira, I.S.; Fernandes, P.A.; Ramos, M.J. Hot spots-a review of the protein-protein interface determinant amino-acid residues. Proteins: Struct., Funct., Bioinf., 2007, 68, 803-812.
18. Mancera, R.L. Molecular modeling of hydration in drug design. Curr. Opin. Drug Discov. Dev., 2007, 10, 275-280.
19. Gonzalez-Ruiz, D.; Gohlke, H. Targeting protein-protein interactions with small molecules: challenges and perspectives for computational binding epitope detection and ligand finding. Curr. Med. Chem., 2006, 13, 2607-2625.
20. Tuncbag, N.; Kar, G.; Keskin, O.; Gursoy, A.; Nussinov, R. A survey of available tools and web servers for analysis of proteinprotein interactions and interfaces. Briefings Bioinform., 2009, 10, 217-232.
21. Kirchmair, J.; Markt, P.; Distinto, S.; Schuster, D.; Spitzer, G.M.; Liedl, K.R.; Langer, T.; Wolber, G. The Protein Data Bank (PDB), its related services and software tools as key components for in silico guided drug discovery. J. Med. Chem., 2008, 51, 7021-7040.
22. Fry, D.C.; Vassilev, L.T. Targeting protein-protein interactions for cancer therapy. J. Mol. Med., 2005, 83, 955-963.
23. Cheng, A.C.; Coleman, R.G.; Smyth, K.T.; Cao, Q.; Soulard, P.; Caffrey, D.R.; Salzberg, A.C.; Huang, E.S. Structure-based maximal affinity model predicts small-molecule druggability. Nat. Biotech., 2007, 25, 71-75.
24. Conte, L.L.; Chothia, C.; Janin, J. The atomic structure of proteinprotein recognition sites. J. Mol. Biol., 1999, 285, 2177-2198.
25. Fletcher, S.; Hamilton, A.D. Targeting protein-protein interactions by rational design: mimicry of protein surfaces. J. R. Soc. Interface, 2006, 3, 215-233.
26. Jones, S.; Thornton, J.M. Principles of protein-protein interactions. Proc. Natl. Acad. Sci. U. S. A., 1996, 93, 13-20.
27. Smith, R.D.; Hu, L.; Falkner, J.A.; Benson, M.L.; Nerothin, J.P.; Carlson, H.A. Exploring protein-ligand recognition with Binding MOAD. J. Mol. Graphics Modell., 2006, 24, 414-425.
28. Janin, J.; Chothia, C. The structure of protein-protein recognition sites. J. Biol. Chem., 1990, 265, 16027-16030.
29. Pettit, F.K.; Bowie, J.U. Protein surface roughness and small molecular binding sites. J. Mol. Biol., 1999, 285, 1377-1382.
30. Higueruelo, A.P.; Schreyer, A.; Bickerton, G.R.J.; Pitt, W.R.; Groom, C.R.; Blundell, T.L. Atomic interactions and profile of small molecules disrupting protein-protein interfaces: the TIMBAL database. Chem. Biol. Drug Des., 2009, 74, 457-467.
31. Goh, C.S.; Milburn, D.; Gerstein, M. Conformational changes associated with protein-protein interactions. Curr. Opin. Struct. Biol., 2004, 14, 104-109.
32. DeLano, W.L.; Ultsch, M.H.; de Vos, A.M.; Wells, J.A. Convergent solutions to binding at a protein-protein interface. Science, 2000, 287, 1279-1283.
33. Sundberg, E.J.; Mariuzza, R.A. Luxury accommodations: the expanding role of structural plasticity in protein-protein interactions. Structure, 2000, 8, R137-R142.
34. Scott, P.B.; Philip, J.H. Effects of conformational dynamics on predicted protein druggability. ChemMedChem, 2006, 1, 70-72.
35. Eyrisch, S.; Helms, V. Transient pockets on protein surfaces involved in protein-protein interaction. J. Med. Chem., 2007, 50, 3457-3464.
36. Young, L.; Jernigan, R.L.; Covell, D.G. A role for surface hydrophobicity in protein-protein recognition. Protein Sci., 1994, 3, 717-729.
37. Korn, A.P.; Burnett, R.M. Distribution and complementarity of hydropathy in multisubunit proteins. Proteins: Struct., Funct., Genet., 1991, 9, 37-55.
38. Fernandez, A.; Scheraga, H.A. Insufficiently dehydrated hydrogen bonds as determinants of protein interactions. Proc. Natl. Acad. Sci. U. S. A., 2003, 100, 113-118.
39. Glaser, F.; Steinberg, D.M.; Vakser, I.A.; Ben-Tal, N. Residue frequencies and pairing preferences at protein-protein interfaces. Proteins: Struct., Funct., Genet., 2001, 43, 89-102.
40. Camacho, C.J.; Weng, Z.P.; Vajda, S.; DeLisi, C. Free energy landscapes of encounter complexes in protein-protein association. Biophys. J., 1999, 76, 1166-1178.
41. Sheinerman, F.B.; Norel, R.; Honig, B. Electrostatic aspects of protein-protein interactions. Curr. Opin. Struct. Biol., 2000, 10, 153-159.
42. Vijayakumar, M.; Wong, K.Y.; Schreiber, G.; Fersht, A.R.; Szabo, A.; Zhou, H.X. Electrostatic enhancement of diffusion-controlled protein-protein association: comparison of theory and experiment on barnase and barstar. J. Mol. Biol., 1998, 278, 1015-1024.
43. Xu, D.; Lin, S.L.; Nussinov, R. Protein binding versus protein folding: the role of hydrophilic bridges in protein associations. J. Mol. Biol., 1997, 265, 68-84.
44. Xu, D.; Tsai, C.J.; Nussinov, R. Hydrogen bonds and salt bridges across protein-protein interfaces. Protein Eng., 1997, 10, 999-1012.
45. Juliano, R.L.; Astriab-Fisher, A.; Falke, D. Macromolecular therapeutics: emerging strategies for drug discovery in the postgenome era. Mol. Interv., 2001, 1, 40-53.
46. Lipinski, C.A. Drug-like properties and the causes of poor solubility and poor permeability. J. Pharmacol. Toxicol. Methods, 2000, 44, 235-249.
47. Lipinski, C.A.; Lombardo, F.; Dominy, B.W.; Feeney, P.J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev., 1997, 23, 3-25.
48. Ma, B.Y.; Elkayam, T.; Wolfson, H.; Nussinov, R. Protein-protein interactions: structurally conserved residues distinguish between binding sites and exposed protein surfaces. Proc. Natl. Acad. Sci. USA, 2003, 100, 5772-5777.
49. DeLano, W.L. Unraveling hot spots in binding interfaces: progress and challenges. Curr. Opin. Struct. Biol., 2002, 12, 14-20.
50. Clackson, T.; Wells, J. A hot spot of binding energy in a hormonereceptor interface. Science, 1995, 267, 383-386.
51. Clackson, T.; Ultsch, M.H.; Wells, J.A.; de Vos, A.M. Structural and functional analysis of the 1:1 growth hormone:receptor complex reveals the molecular basis for receptor affinity. J. Mol. Biol., 1998, 277, 1111-1128.
52. Muller, Y.A.; Li, B.; Christinger, H.W.; Wells, J.A.; Cunningham, B.C.; de Vos, A.M. Vascular endothelial growth factor: crystal structure and functional mapping of the kinase domain receptor binding-site. Proc. Natl. Acad. Sci. U. S. A., 1997, 94, 7192-7197.
53. Thanos, C.D.; DeLano, W.L.; Wells, J.A. Hot-spot mimicry of a cytokine receptor by a small molecule. Proc. Natl. Acad. Sci. U. S. A., 2006, 103, 15422-15427.
54. Arkin, M.R.; Randal, M.; DeLano, W.L.; Hyde, J.; Luong, T.N.; Oslob, J.D.; Raphael, D.R.; Taylor, L.; Wang, J.; McDowell, R.S.; Wells, J.A.; Braisted, A.C. Binding of small molecules to an adap tive protein-protein interface. Proc. Natl. Acad. Sci. U. S. A., 2003, 100, 1603-1608.
55. Bogan, A.A.; Thorn, K.S. Anatomy of hot spots in protein interfaces. J. Mol. Biol., 1998, 280, 1-9.
56. Ma, B.; Nussinov, R. Trp/Met/Phe hot spots in protein-protein interactions: potential targets in drug design. Curr. Top. Med. Chem. (Sharjah, United Arab Emirates), 2007, 7, 999-1005.
57. Ofran, Y.; Rost, B. Analysing six types of protein-protein interfaces. J. Mol. Biol., 2003, 325, 377-387.
58. Ofran, Y.; Rost, B. Protein-protein interaction hotspots carved into sequences. PLoS Comput. Biol., 2007, 3, 1169-1176.
59. Cochran, A.G. Protein-protein interfaces: mimics and inhibitors. Curr. Opin. Chem. Biol., 2001, 5, 654-659.
60. Hershberger, S.J.; Lee, S.G.; Chmielewski, J. Scaffolds for blocking protein-protein interactions. Curr. Top. Med. Chem. (Sharjah, United Arab Emirates), 2007, 7, 928-942.
61. Fletcher, S.; Hamilton, A.D. Protein surface recognition and proteomimetics: mimics of protein surface structure and function. Curr. Opin. Chem. Biol., 2005, 9, 632-638.
62. Haridas, V. From peptides to non-peptide alpha-helix inducers and mimetics. Eur. J. Org. Chem., 2009, 30, 5112-5128.
63. Yin, H.; Hamilton, A.D. Protein secondary structure mimetics as modulators of protein-protein and protein-ligand interactions. Chem. Biol., 2007, 1, 250-269.
64. Che, Y.; Brooks, B.R.; Marshall, G.R. Development of small molecules designed to modulate protein-protein interactions. J. Comput.-Aided Mol. Des., 2006, 20, 109-130.
65. Orner, B.P.; Ernst, J.T.; Hamilton, A.D. Toward proteomimetics: terphenyl derivatives as structural and functional mimics of extended regions of an alpha-helix. J. Am. Chem. Soc., 2001, 123, 5382-5383.
66. Cochran, A.G.; Tong, R.T.; Starovasnik, M.A.; Park, E.J.; McDowell, R.S.; Theaker, J.E.; Skelton, N.J. A minimal peptide scaffold for beta-turn display: optimizing a strand position in disulfide-cyclized beta-hairpins. J. Am. Chem. Soc., 2000, 123, 625-632.
67. Cochran, A.G.; Skelton, N.J.; Starovasnik, M.A. Tryptophan zippers: stable, monomeric beta-hairpins. Proc. Natl. Acad. Sci. U. S. A., 2001, 98, 5578-5583.
68. Moellering, R.E.; Cornejo, M.; Davis, T.N.; Bianco, C.D.; Aster, J.C.; Blacklow, S.C.; Kung, A.L.; Gilliland, D.G.; Verdine, G.L.; Bradner, J.E. Direct inhibition of the NOTCH transcription factor complex. Nature, 2009, 462, 182-188.
69. Villoutreix Bruno, O.; Bastard, K.; Sperandio, O.; Fahraeus, R.; Poyet, J.-L.; Calvo, F.; Deprez, B.; Miteva Maria, A. In silico-in vitro screening of protein-protein interactions: towards the next generation of therapeutics. Curr. Pharm. Biotechnol., 2008, 9, 103-122.
70. Zhong, S.J.; Macias, A.T.; MacKerell, A.D. Computational identification of inhibitors of protein-protein interactions. Curr. Top. Med. Chem. (Sharjah, United Arab Emirates), 2007, 7, 63-82.
71. Kirchmair, J.; Distinto, S.; Schuster, D.; Spitzer, G.; Langer, T.; Wolber, G. Enhancing drug discovery through in-silico screening: strategies to increase true positives retrieval rates. Curr. Med. Chem., 2008, 15, 2040-2053.
72. Grosdidier, S.; Fernandez-Recio, J. Docking and scoring: applications to drug discovery in the interactomics era. Expert Opin. Drug Discovery, 2009, 4, 673-686.
73. Kirchmair, J.; Laggner, C.; Wolber, G.; Langer, T. Comparative analysis of protein-bound ligand conformations with respect to Catalyst's conformational space subsampling algorithms. J. Chem. Inf. Model., 2005, 45, 422-430.
74. Kirchmair, J.; Ristic, S.; Eder, K.; Markt, P.; Wolber, G.; Laggner, C.; Langer, T. Fast and efficient in silico 3D screening: toward maximum computational efficiency of pharmacophore-based and shape-based approaches. J. Chem. Inf. Model., 2007, 47, 2182-2196.
75. Kirchmair, J.; Wolber, G.; Laggner, C.; Langer, T. Comparative performance assessment of the conformational model generators Omega and Catalyst: a large-scale survey on the retrieval of protein-bound ligand conformations. J. Chem. Inf. Model., 2006, 46, 1848-1861.
76. Li, J.; Ehlers, T.; Sutter, J.; Varma-O'Brien, S.; Kirchmair, J. CAESAR: a new conformer generation algorithm based on recursive buildup and local rotational symmetry consideration. J. Chem. Inf. Model., 2007, 47, 1923-1932.
77. Rarey, M.; Kramer, B.; Lengauer, T. The particle concept: placing discrete water molecules during protein-ligand docking predictions. Proteins: Struct., Funct., Genet., 1999, 34, 17-28.
78. Shoichet, B.K.; Leach, A.R.; Kuntz, I.D. Ligand solvation in molecular docking. Proteins: Struct., Funct., Genet., 1999, 34, 4-16.
79. Huang, N.; Shoichet, B.K. Exploiting ordered waters in molecular docking. J. Med. Chem., 2008, 51, 4862-4865.
80. Verdonk, M.L.; Chessari, G.; Cole, J.C.; Hartshorn, M.J.; Murray, C.W.; Nissink, J.W.M.; Taylor, R.D.; Taylor, R. Modeling water molecules in protein-ligand docking using GOLD. J. Med. Chem., 2005, 48, 6504-6515.
81. Villacanas, O.; Madurga, S.; Giralt, E.; Belda, I. Explicit treatment of water molecules in protein-ligand docking. Curr. Comput.-Aided Drug Des., 2009, 5, 145-154.
82. Friesner, R.A.; Banks, J.L.; Murphy, R.B.; Halgren, T.A.; Klicic, J.J.; Mainz, D.T.; Repasky, M.P.; Knoll, E.H.; Shelley, M.; Perry, J.K.; Shaw, D.E.; Francis, P.; Shenkin, P.S. Glide: A new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J. Med. Chem., 2004, 47, 1739-1749.
83. Friesner, R.A.; Murphy, R.B.; Repasky, M.P.; Frye, L.L.; Greenwood, J.R.; Halgren, T.A.; Sanschagrin, P.C.; Mainz, D.T. Extra precision GLIDE: Docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. J. Med. Chem., 2006, 49, 6177-6196.
84. Schnecke, V.; Kuhn, L.A. Virtual screening with solvation and ligand-induced complementarity. Perspect. Drug Discov. Des., 2000, 20, 171-190.
85. van Dijk, A.D.J.; Bonvin, A. Solvated docking: introducing water into the modelling of biomolecular complexes. Bioinformatics, 2006, 22, 2340-2347.
86. Deng, W.; Verlinde, C. Evaluation of different virtual screening programs for docking in a charged binding pocket. J. Chem. Inf. Model., 2008, 48, 2010-2020.
87. Englebienne, P.; Moitessier, N. Docking ligands into flexible and solvated macromolecules. 4. Are popular scoring functions accurate for this class of proteins? J. Chem. Inf. Model., 2009, 49, 1568-1580.
88. Corbeil, C.R.; Englebienne, P.; Moitessier, N. Docking ligands into flexible and solvated macromolecules. 1. Development and validation of FITTED 1.0. J. Chem. Inf. Model., 2007, 47, 435-449.
89. Garcia-Sosa, A.T.; Mancera, R.L.; Dean, P.M. WaterScore: a novel method for distinguishing between bound and displaceable water molecules in the crystal structure of the binding site of proteinligand complexes. J. Mol. Model., 2003, 9, 172-182.
90. Goodford, P.J. A computational procedure for determining energetically favorable binding-sites on biologically important macromolecules. J. Med. Chem., 1985, 28, 849-857.
91. Kellogg, G.E.; Abraham, D.J. Hydrophobicity: is LogP(o/w) more than the sum of its parts? Eur. J. Med. Chem., 2000, 35, 651-661.
92. Kellogg, G.E.; Chen, D.L. The importance of being exhaustive. Optimization of bridging structural water molecules and water networks in models of biological systems. Chem. Biodivers., 2004, 1, 98-105.
93. Kortvelyesi, T.; Dennis, S.; Silberstein, M.; Brown, L.; Vajda, S. Algorithms for computational solvent mapping of proteins. Proteins: Struct., Funct., Genet., 2003, 51, 340-351.
94. Raymer, M.L.; Sanschagrin, P.C.; Punch, W.F.; Venkataraman, S.; Goodman, E.D.; Kuhn, L.A. Predicting conserved water-mediated and polar ligand interactions in proteins using a K-nearestneighbors genetic algorithm. J. Mol. Biol., 1997, 265, 445-464.
95. Schymkowitz, J.W.H.; Rousseau, F.; Martins, I.C.; Ferkinghoff-Borg, J.; Stricher, F.; Serrano, L. Prediction of water and metal binding sites and their affinities by using the Fold-X force field. Proc. Natl. Acad. Sci. USA, 2005, 102, 10147-10152.
96. Verdonk, M.L.; Cole, J.C.; Taylor, R. SuperStar: a knowledgebased approach for identifying interaction sites in proteins. J. Mol. Biol., 1999, 289, 1093-1108.
97. Verdonk, M.L.; Cole, J.C.; Watson, P.; Gillet, V.; Willett, P. SuperStar: improved knowledge-based interaction fields for protein binding sites. J. Mol. Biol., 2001, 307, 841-859.
98. Cole, J.L.; Lary, J.W.; Moody, T.P.; Laue, T.M. Analytical ULTracentrifugation: Sedimentation Velocity and Sedimentation Equilibrium. In Biophysical Tools for Biologists: Vol 1 in Vitro Techniques; Elsevier Academic Press Inc: San Diego, 2008; Vol. 84, pp. 143-179.
99. Huber, W.; Mueller, F. Biomolecular interaction analysis in drug discovery using surface plasmon resonance technology. Curr. Pharm. Des., 2006, 12, 3999-4021.
100. Liang, Y. Applications of isothermal titration calorimetry in protein science. Acta Biochim. Biophys. Sin., 2008, 40, 565-576.
101. Vicent, M.J.; Perez-Paya, E.; Orzaez, M. Discovery of inhibitors of protein-protein interactions from combinatorial libraries. Curr. Top. Med. Chem., 2007, 7, 83-95.
102. Braisted, A.C.; Oslob, J.D.; Delano, W.L.; Hyde, J.; McDowell, R.S.; Waal, N.; Yu, C.; Arkin, M.R.; Raimundo, B.C. Discovery of a potent small molecule IL-2 inhibitor through fragment assembly. J. Am. Chem. Soc., 2003, 125, 3714-3715.
103. Liu, G.; Link, J.T.; Pei, Z.; Reilly, E.B.; Leitza, S.; Nguyen, B.; Marsh, K.C.; Okasinski, G.F.; von Geldern, T.W.; Ormes, M.; Fowler, K.; Gallatin, M. Discovery of novel p-arylthio cinnamides as antagonists of leukocyte function-associated antigen-1/intracellular adhesion molecule-1 interaction. 1. Identification of an additional binding pocket based on an anilino diaryl sulfide lead. J. Med. Chem., 2000, 43, 4025-4040.
104. Smith, C.M.; Shindyalov, I.N.; Veretnik, S.; Gribskov, M.; Taylor, S.S.; TenEyck, L.F.; Bourne, P.E. The protein kinase resource. Trends Biochem. Sci., 1997, 22, 444-446.
105. Fischer, P.M. The design of drug candidate molecules as selective inhibitors of therapeutically relevant protein kinases. Curr. Med. Chem., 2004, 11, 1563-1583.
106. Buchdunger, E.; Zimmermann, J.; Mett, H.; Meyer, T.; Muller, M.; Druker, B.J.; Lydon, N.B. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res., 1996, 56, 100-104.
107. Buchdunger, E.; Cioffi, C.L.; Law, N.; Stover, D.; Ohno-Jones, S.; Druker, B.J.; Lydon, N.B. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-Kit and platelet-derived growth factor receptors. J. Pharmacol. Exp. Ther., 2000, 295, 139-145.
108. Papaetis, G.S.; Syrigos, K.N. Sunitinib: a multitargeted receptor tyrosine kinase inhibitor in the era of molecular cancer therapies. BioDrugs, 2009, 23, 377-389.
109. Wilhelm, S.M.; Carter, C.; Tang, L.Y.; Wilkie, D.; McNabola, A.; Rong, H.; Chen, C.; Zhang, X.M.; Vincent, P.; McHugh, M.; Cao, Y.C.; Shujath, J.; Gawlak, S.; Eveleigh, D.; Rowley, B.; Liu, L.; Adnane, L.; Lynch, M.; Auclair, D.; Taylor, I.; Gedrich, R.; Voznesensky, A.; Riedl, B.; Post, L.E.; Bollag, G.; Trail, P.A. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res., 2004, 64, 7099-7109.
110. Kirkland, L.O.; McInnes, C. Non-ATP competitive protein kinase inhibitors as anti-tumor therapeutics. Biochem. Pharmacol., 2009, 77, 1561-1571.
111. Duesbery, N.S.; Webb, C.P.; Woude, G.F.V. MEK Wars, a new front in the battle against cancer. Nat. Med., 1999, 5, 736-737.
112. Shapiro, P. Ras-MAP kinase signaling pathways and control of cell proliferation: Relevance to cancer therapy. Crit. Rev. Clin. Lab. Sci., 2002, 39, 285-330.
113. Hancock, C.N.; Macias, A.; Lee, E.K.; Yu, S.Y.; MacKerell, A.D.; Shapiro, P. Identification of novel extracellular signal-regulated kinase docking domain inhibitors. J. Med. Chem., 2005, 48, 4586-4595.
114. Kuntz, I.D.; Blaney, J.M.; Oatley, S.J.; Langridge, R.; Ferrin, T.E. A geometric approach to macromolecule-ligand interactions. J. Mol. Biol., 1982, 161, 269-288.
115. Li, Q.; Al-Ayoubi, A.; Guo, T.; Zheng, H.; Sarkar, A.; Nguyen, T.; Eblen, S.T.; Grant, S.; Kellogg, G.E.; Zhang, S. Structure-activity relationship (SAR) studies of 3-(2-amino-ethyl)-5-(4-ethoxybenzylidene)-thiazolidine-2,4-dione: development of potential substrate-specific ERK1/2 inhibitors. Bioorg. Med. Chem. Lett., 2009, 19, 6042-6046.
116. Benati, D.; Baldari, C.T. Src family kinases as potential therapeutic targets for malignancies and immunological disorders. Curr. Med. Chem., 2008, 15, 1154-1165.
117. Cousins-Wasti, R.C.; Ingraham, R.H.; Morelock, M.M.; Grygon, C.A. Determination of affinities for lck SH2 binding peptides using a sensitive fluorescence assay: Comparison between the pYEEIP and pYQPQP consensus sequences reveals context-dependent binding specificity. Biochemistry, 1996, 35, 16746-16752.
118. Huang, N.; Nagarsekar, A.; Xia, G.J.; Hayashi, J.; MacKerell, A.D. Identification of non-phosphate-containing small molecular weight inhibitors of the tyrosine kinase p56 Lck SH2 domain via in silico screening against the pY+3 binding site. J. Med. Chem., 2004, 47, 3502-3511.
119. Macias, A.T.; Mia, M.Y.; Xia, G.J.; Hayashi, J.; MacKerell, A.D. Lead validation and SAR development via chemical similarity searching: application to compounds targeting the pY+3 site of the SH2 domain of p56(lck). J. Chem. Inf. Model., 2005, 45, 1759-1766.
120. Won, J.; Hur, Y.G.; Hur, E.M.; Park, S.H.; Kang, M.A.; Choi, Y.; Park, C.; Lee, K.H.; Yun, Y. Rosmarinic acid inhibits TCR-induced T cell activation and proliferation in an Lck-dependent manner. Eur. J. Immunol., 2003, 33, 870-879.
121. Park, S.H.; Oh, H.S.; Kang, M.A.; Cho, H.J.; Prasad, J.B.; Won, J.; Lee, K.H. The structure-activity relationship of the series of nonpeptide small antagonists for p561ck SH2 domain. Bioorg. Med. Chem., 2007, 15, 3938-3950.
122. Reindl, W.G.; Yuan, J.P.; Kramer, A.; Strebhardt, K.; Berg, T. Inhibition of polo-like kinase 1 by blocking polo-box domaindependent protein-protein interactions. Chem. Biol., 2008, 15, 459-466.
123. Reindl, W.; Yuan, J.P.; Kramer, A.; Strebhardt, K.; Berg, T. Inhibition of polo-like kinase 1 by blocking polo-box domain-dependent protein-protein interactions. ChemBioChem, 2009, 10, 1145-1148.
124. Watanabe, N.; Sekine, T.; Takagi, M.; Iwasaki, J.; Imamoto, N.; Kawasaki, H.; Osada, H. Deficiency in chromosome congression by the inhibition of Plk1 polo box domain-dependent recognition. J. Biol. Chem., 2009, 284, 2344-2353.
125. Andrews, M.J.I.; Kontopidis, G.; McInnes, C.; Plater, A.; Innes, L.; Cowan, A.; Jewsbury, P.; Fischer, P.M. REPLACE: A strategy for iterative design of cyclin-binding groove inhibitors. ChemBioChem, 2006, 7, 1909-1915.
126. Tsai, L.H.; Harlow, E.; Meyerson, M. Isolation of the human cdk2 gene that encodes the cyclin A-and adenovirus E1A-associated p33 kinase. Nature, 1991, 353, 174-177.
127. Zheleva, D.I.; McInnes, C.; Gavine, A.L.; Zhelev, N.Z.; Fischer, P.M.; Lane, D.P. Highly potent p21(WAF1)-derived peptide inhibitors of CDK-mediated pRb phosphorylation: delineation and structural insight into their interactions with cyclin A. J. Pept. Res., 2002, 60, 257-270.
128. Venkatachalam, C.M.; Jiang, X.; Oldfield, T.; Waldman, M. LigandFit: a novel method for the shape-directed rapid docking of ligands to protein active sites. J. Mol. Graph. Modell., 2003, 21, 289-307.
129. Fields, A.P.; Frederick, L.A.; Regala, R.P. Targeting the oncogenic protein kinase C-l signalling pathway for the treatment of cancer. Biochem. Soc. Trans., 2007, 35, 996-1000.
130. Regala, R.P.; Davis, R.K.; Kunz, A.; Khoor, A.; Leitges, M.; Fields, A.P. Atypical protein kinase C iota is required for bronchioalveolar stem cell expansion and lung tumorigenesis. Cancer Res., 2009, 69, 7603-7611.
131. Roffey, J.; Rosse, C.; Linch, M.; Hibbert, A.; McDonald, N.Q.; Parker, P.J. Protein kinase C intervention-the state of play. Curr. Opin. Cell Biol., 2009, 21, 268-279.
132. Stallings-Mann, M.; Jamieson, L.; Regala, R.P.; Weems, C.; Murray, N.R.; Fields, A.P. A novel small-molecule inhibitor of protein kinase C iota blocks transformed growth of non-small-cell lung cancer cells. Cancer Res., 2006, 66, 1767-1774.
133. Erdogan, E.; Lamark, T.; Stallings-Mann, M.; Jamieson, L.; Pellechia, M.; Thompson, E.A.; Johansen, T.; Fields, A.P. Aurothiomalate inhibits transformed growth by targeting the PB1 domain of protein kinase C iota. J. Biol. Chem., 2006, 281, 28450-28459.
134. Mischak, H.; Goodnight, J.; Kolch, W.; Martinybaron, G.; Schaechtle, C.; Kazanietz, M.G.; Blumberg, P.M.; Pierce, J.H.; Mushinski, J.F. Overexpression of protein kinase C-delta and-epsilon in NIH 3T3 cells induces opposite effects on growth, morphology, anchorage dependence, and tumorigenicity. J. Biol. Chem., 1993, 268, 6090-6096.
135. Malhotra, A.; Reich, D.; Nakouzi, A.; Sanghi, V.; Geenen, D.L.; Buttrick, P.M. Experimental diabetes is associated with functional activation of protein kinase C epsilon and phosphorylation of troponin I in the heart, which are prevented by angiotensin II receptor blockade. Circ. Res., 1997, 81, 1027-1033.
136. Dorn, G.W.; Souroujon, M.C.; Liron, T.; Chen, C.H.; Gray, M.O.; Zhou, H.Z.; Csukai, M.; Wu, G.Y.; Lorenz, J.N.; Mochly-Rosen, D. Sustained in vivo cardiac protection by a rationally designed peptide that causes epsilon protein kinase C translocation. Proc. Natl. Acad. Sci. U. S. A., 1999, 96, 12798-12803.
137. Takeishi, Y.; Ping, P.; Bolli, R.; Kirkpatrick, D.L.; Hoit, B.D.; Walsh, R.A. Transgenic overexpression of constitutively active protein kinase C epsilon causes concentric cardiac hypertrophy Circ. Res., 2000, 86, 1218-1223.
138. Cesare, P.; Dekker, L.V.; Sardini, A.; Parker, P.J.; McNaughton, P.A. Specific involvement of PKC-epsilon in sensitization of the neuronal response to painful heat. Neuron, 1999, 23, 617-624.
139. Hodge, C.W.; Mehmert, K.K.; Kelley, S.P.; McMahon, T.; Haywood, A.; Olive, M.F.; Wang, D.; Sanchez-Perez, A.M.; Messing, R.O. Supersensitivity to allosteric GABA(A) receptor modulators and alcohol in mice lacking PKC epsilon. Nat. Neurosci., 1999, 2, 997-1002.
140. Castrillo, A.; Pennington, D.J.; Otto, F.; Parker, P.J.; Owen, M.J.; Bosca, L. Protein kinase C epsilon is required for macrophage activation and defense against bacterial infection. J. Exp. Med., 2001, 194, 1231-1242.
141. Csukai, M.; Chen, C.H.; DeMatteis, M.A.; Mochly-Rosen, D. The coatomer protein beta'-COP, a selective binding protein (RACK) for protein kinase C epsilon. J. Biol. Chem., 1997, 272, 29200-29206.
142. Johnson, J.A.; Gray, M.O.; Chen, C.H.; Mochly-Rosen, D. A protein kinase C translocation inhibitor as an isozyme-selective antagonist of cardiac function. J. Biol. Chem., 1996, 271, 24962-24966.
143. Gruber, P.; Rechfeld, F.; Kirchmair, J.; Hauser, N.; Boehler, M.; Garczarczyk, D.; Langer, T.; Hofmann, J. Barbituric acid derivative BAS 02104951 inhibits PKCepsilon, PKCeta, PKCepsilon/RACK2 interaction, Elk-1 phosphorylation in HeLa and PKCepsilon and eta translocation in PC3 cells following TPA-induction. J. Biochem., 2011, 149, 331-336.
144. Cochran, A.G. Antagonists of protein-protein interactions. Chem. Biol., 2000, 7, R85-R94.
145. Veselovsky, A.V.; Archakov, A.I. Inhibitors of protein-protein interactions as potential drugs. Curr. Comput.-Aided Drug Des., 2007, 3, 51-58.
146. Barber, E.K.; Dasgupta, J.D.; Schlossman, S.F.; Trevillyan, J.M.; Rudd, C.E. The CD4 and CD8 antigens are coupled to a proteintyrosine kinase (p56lck) that phosphorylates the CD3 complex. Proc. Natl. Acad. Sci. U. S. A., 1989, 86, 3277-3281.
147. Doyle, C.; Strominger, J.L. Interaction between CD4 and class II MHC molecules mediates cell adhesion. Nature, 1987, 330, 256-259.
148. Gay, D.; Maddon, P.; Sekaly, R.; Talle, M.A.; Godfrey, M.; Long, E.; Goldstein, G.; Chess, L.; Axel, R.; Kappler, J.; Marrack, P. Functional interaction between human T-cell protein CD4 and the major histocompatibility complex HLA-DR antigen. Nature, 1987, 328, 626-629.
149. Konig, R.; Huang, L.Y.; Germain, R.N. MHC class II interaction with CD4 mediated by a region analogous to the MHC class I binding site for CD8. Nature, 1992, 356, 796-798.
150. Veillette, A.; Bookman, M.A.; Horak, E.M.; Bolen, J.B. The CD4 and CD8 T cell surface antigens are associated with the internal membrane tyrosine-protein kinase p56lck. Cell, 1988, 55, 301-308.
151. Xiao, H.; Feng, J.-N.; He, X.-h.; Zhang, H.; Zhang, J.-R.; Zhang, L.; Yu, M.; Huang, Y.-F.; Li, S.; Shen, B.-F.; Li, Y. Potent inhibition of the CD4-dependent T cell response by J2, a novel nonpeptide organic ligand of CD4 D1. Mol. Immunol., 2007, 44, 784-795.
152. Xiao, H.; Zhang, H.; Yu, Z.Y.; Zhang, L.; Yu, M.; Huang, Y.F.; Li, S.; Shen, B.F.; Li, Y. J2 prolongs the corneal allograft survival through inhibition of the CD4(+) T cell-mediated response in vivo. Transplant Immunol., 2007, 18, 130-137.
153. He, M.M.; Smith, A.S.; Oslob, J.D.; Flanagan, W.M.; Braisted, A.C.; Whitty, A.; Cancilla, M.T.; Wang, J.; Lugovskoy, A.A.; Yoburn, J.C.; Fung, A.D.; Farrington, G.; Eldredge, J.K.; Day, E.S.; Cruz, L.A.; Cachero, T.G.; Miller, S.K.; Friedman, J.E.; Choong, I.C.; Cunningham, B.C. Small-molecule inhibition of TNF-alpha. Science, 2005, 310, 1022-1025.
154. Raimundo, B.C.; Oslob, J.D.; Braisted, A.C.; Hyde, J.; McDowell, R.S.; Randal, M.; Waal, N.D.; Wilkinson, J.; Yu, C.H.; Arkin, M.R. Integrating fragment assembly and biophysical methods in the chemical advancement of small-molecule antagonists of IL-2: an approach for inhibiting protein-protein interactions. J. Med. Chem., 2004, 47, 3111-3130.
155. Moerke, N.J.; Aktas, H.; Chen, H.; Cantel, S.; Reibarkh, M.Y.; Fahmy, A.; Gross, J.D.; Degterev, A.; Yuan, J.Y.; Chorev, M.; Halperin, J.A.; Wagner, G. Small-molecule inhibition of the interaction between the translation initiation factors eIF4E and eIF4G. Cell, 2007, 128, 257-267.
156. Eguchi, M.; Nguyen, C.; Lee, S.C.; Kahn, M. ICG-001, a novel small molecule regulator of TCF/beta-catenin transcription. Med. Chem., 2005, 1, 467-472.
157. Emami, K.H.; Nguyen, C.; Ma, H.; Kim, D.H.; Jeong, K.W.; Eguchi, M.; Moon, R.T.; Teo, J.-L.; Oh, S.W.; Kim, H.Y.; Moon, S.H.; Ha, J.R.; Kahn, M. A small molecule inhibitor of betacatenin/ cyclic AMP response element-binding protein transcription. Proc. Natl. Acad. Sci. U. S. A., 2004, 101, 12682-12687.
158. McMartin, C.; Bohacek, R.S. QXP: Powerful, rapid computer algorithms for structure-based drug design. J. Comput.-Aided Mol. Des., 1997, 11, 333-344.
159. Trosset, J.Y.; Dalvit, C.; Knapp, S.; Fasolini, M.; Veronesi, M.; Mantegani, S.; Gianellini, L.M.; Catana, C.; Sundstrom, M.; Stouten, P.F.W.; Moll, J.K. Inhibition of protein-protein interactions: The discovery of druglike beta-catenin inhibitors by combining virtual and biophysical screening. Proteins: Struct., Funct., Bioinform., 2006, 64, 60-67.
160. Fujii, N.; You, L.; Xu, Z.; Uematsu, K.; Shan, J.; He, B.; Mikami, I.; Edmondson, L.R.; Neale, G.; Zheng, J.; Guy, R.K.; Jablons, D.M. An antagonist of dishevelled protein-protein interaction suppresses beta-catenin-dependent tumor cell growth. Cancer Res., 2007, 67, 573-579.
161. Haffner, R.; Oren, M. Biochemical properties and biological effects of p53. Curr. Opin. Genet. Dev., 1995, 5, 84-90.
162. Levine, A.J.; Hu, W.; Feng, Z. The P53 pathway: what questions remain to be explored? Cell Death Differ., 2006, 13, 1027-1036.
163. Vassilev, L.T.; Vu, B.T.; Graves, B.; Carvajal, D.; Podlaski, F.; Filipovic, Z.; Kong, N.; Kammlott, U.; Lukacs, C.; Klein, C.; Fotouhi, N.; Liu, E.A. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science, 2004, 303, 844-848.
164. Grasberger, B.L.; Lu, T.B.; Schubert, C.; Parks, D.J.; Carver, T.E.; Koblish, H.K.; Cummings, M.D.; LaFrance, L.V.; Milkiewicz, K.L.; Calvo, R.R.; Maguire, D.; Lattanze, J.; Franks, C.F.; Zhao, S.Y.; Ramachandren, K.; Bylebyl, G.R.; Zhang, M.; Manthey, C.L.; Petrella, E.C.; Pantoliano, M.W.; Deckman, I.C.; Spurlino, J.C.; Maroney, A.C.; Tomczuk, B.E.; Molloy, C.J.; Bone, R.F. Discovery and cocrystal structure of benzodiazepinedione HDM2 antagonists that activate p53 in cells. J. Med. Chem., 2005, 48, 909-912.
165. Parks, D.J.; LaFrance, L.V.; Calvo, R.R.; Milkiewicz, K.L.; Gupta, V.; Lattanze, J.; Ramachandren, K.; Carver, T.E.; Petrella, E.C.; Cummings, M.D.; Maguire, D.; Grasberger, B.L.; Lu, T.B. 1,4-benzodiazepine-2,5-diones as small molecule antagonists of the HDM2-p53 interaction: discovery and SAR. Bioorg. Med. Chem. Lett., 2005, 15, 765-770.
166. Koblish, H.K.; Zhao, S.Y.; Franks, C.F.; Donatelli, R.R.; Tominovich, R.M.; LaFrance, L.V.; Leonard, K.A.; Gushue, J.M.; Parks, D.J.; Calvo, R.R.; Milkiewicz, K.L.; Marugan, J.J.; Raboisson, P.; Cummings, M.D.; Grasberger, B.L.; Johnson, D.L.; Lu, T.B.; Molloy, C.J.; Maroney, A.C. Benzodiazepinedione inhibitors of the Hdm2: p53 complex suppress human tumor cell proliferation in vitro and sensitize tumors to doxorubicin in vivo. Mol. Cancer Ther., 2006, 5, 160-169.
167. Shangary, S.; Qin, D.G.; McEachern, D.; Liu, M.L.; Miller, R.S.; Qiu, S.; Nikolovska-Coleska, Z.; Ding, K.; Wang, G.P.; Chen, J.Y.; Bernard, D.; Zhang, J.; Lu, Y.P.; Gu, Q.Y.; Shah, R.B.; Pienta, K.J.; Ling, X.L.; Kang, S.M.; Guo, M.; Sun, Y.; Yang, D.J.; Wang, S.M. Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition. Proc. Natl. Acad. Sci. U. S. A., 2008, 105, 3933-3938.
168. Murray, J.K.; Gellman, S.H. Targeting protein-protein interactions: lessons from p53/MDM2. Biopolymers, 2007, 88, 657-686.
169. Rustandi, R.R.; Baldisseri, D.M.; Weber, D.J. Structure of the negative regulatory domain of p53 bound to S100B(beta beta). Nat. Struct. Biol., 2000, 7, 570-574.
170. Markowitz, J.; Chen, J.; Gitti, R.; Baldisseri, D.M.; Pan, Y.P.; Udan, R.; Carrier, F.; MacKerell, A.D.; Weber, D.J. Identification and characterization of small molecule inhibitors of the calcium dependent S100B-p53 tumor suppressor interaction. J. Med. Chem., 2004, 47, 5085-5093.
171. Huang, Z.W. Bcl-2 family proteins as targets for anticancer drug design. Oncogene, 2000, 19, 6627-6631.
172. Zheng, T.S. Death by design: the big debut of small molecules. Nat. Cell Biol., 2001, 3, E43-E46.
173. Adams, J.M.; Cory, S. The Bcl-2 protein family: arbiters of cell survival. Science, 1998, 281, 1322-1326.
174. Strasser, A.; O'Connor, L.; Dixit, V.M. Apoptosis signaling. Annu. Rev. Biochem., 2000, 69, 217-245.
175. Sattler, M.; Liang, H.; Nettesheim, D.; Meadows, R.P.; Harlan, J.E.; Eberstadt, M.; Yoon, H.S.; Shuker, S.B.; Chang, B.S.; Minn, A.J.; Thompson, C.B.; Fesik, S.W. Structure of Bcl-x(L)-Bak peptide complex: recognition between regulators of apoptosis. Science, 1997, 275, 983-986.
176. Beauparlant, P.; Shore, G.C. Therapeutic activation of caspases in cancer: a question of selectivity. Curr. Opin. Drug Discov. Dev., 2003, 6, 179-187.
177. O'Neill, J.; Manion, M.; Schwartz, P.; Hockenbery, D.M. Promises and challenges of targeting Bcl-2 anti-apoptotic proteins for cancer therapy. Biochim. Biophys. Acta-Rev. Cancer, 2004, 1705, 43-51.
178. Petros, A.M.; Nettesheim, D.G.; Wang, Y.; Olejniczak, E.T.; Meadows, R.P.; Mack, J.; Swift, K.; Matayoshi, E.D.; Zhang, H.C.; Thompson, C.B.; Fesik, S.W. Rationale for Bcl-x(L)/Bad peptide complex formation from structure, mutagenesis, and biophysical studies. Protein Sci., 2000, 9, 2528-2534.
179. Sadowsky, J.D.; Murray, J.K.; Tomita, Y.; Gellman, S.H. Exploration of backbone space in foldamers containing alpha-and betaamino acid residues: Developing protease-resistant oligomers that bind tightly to the BH3-recognition cleft of Bcl-x(L). ChemBioChem, 2007, 8, 903-916.
180. Walensky, L.D.; Kung, A.L.; Escher, I.; Malia, T.J.; Barbuto, S.; Wright, R.D.; Wagner, G.; Verdine, G.L.; Korsmeyer, S.J. Activation of apoptosis in vivo by a hydrocarbon-stapled BH3 helix. Science, 2004, 305, 1466-1470.
181. Yin, H.; Lee, G.I.; Sedey, K.A.; Kutzki, O.; Park, H.S.; Omer, B.P.; Ernst, J.T.; Wang, H.G.; Sebti, S.M.; Hamilton, A.D. Terphenylbased bak BH3 alpha-helical proteomimetics as low-molecularweight antagonists of Bcl-X-L. J. Am. Chem. Soc., 2005, 127, 10191-10196.
182. Kang, M.H.; Reynolds, C.P. Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy. Clin. Cancer Res., 2009, 15, 1126-1132.
183. Ambrosini, G.; Adida, C.; Altieri, D.C. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat. Med., 1997, 3, 917-921.
184. Altieri, D.C. Blocking survivin to kill cancer cells. Methods Mol. Biol., 2003, 223, 533-542.
185. Altieri, D.C. Survivin in apoptosis control and cell cycle regulation in cancer. Prog. Cell Cycle Res., 2003, 5, 447-452.
186. Wendt, M.D.; Sun, C.H.; Kunzer, A.; Sauer, D.; Sarris, K.; Hoff, E.; Yu, L.P.; Nettesheim, D.G.; Chen, J.; Jin, S.; Comess, K.M.; Fan, Y.H.; Anderson, S.N.; Isaac, B.; Olejniczak, E.T.; Hajduk, P.J.; Rosenberg, S.H.; Elmore, S.W. Discovery of a novel small molecule binding site of human survivin. Bioorg. Med. Chem. Lett., 2007, 17, 3122-3129.
187. Yoakim, C.; Ogilvie, W.W.; Goudreau, N.; Naud, J.; Hache, B.; O'Meara, J.A.; Cordingley, M.G.; Archambault, J.; White, P.W. Discovery of the first series of inhibitors of human papillomavirus type 11: inhibition of the assembly of the E1-E2-origin DNA complex. Bioorg. Med. Chem. Lett., 2003, 13, 2539-2541.
188. Goudreau, N.; Cameron, D.R.; Deziel, R.; Hache, B.; Jakalian, A.; Malenfant, E.; Naud, J.; Ogilvie, W.W.; O'Meara, J.; White, P.W.; Yoakim, C. Optimization and determination of the absolute configuration of a series of potent inhibitors of human papillomavirus type-11 E1-E2 protein-protein interaction: a combined medicinal chemistry, NMR and computational chemistry approach. Bioorg. Med. Chem., 2007, 15, 2690-2700.
189. Wang, Y.; Coulombe, R.; Cameron, D.R.; Thauvette, L.; Massariol, M.J.; Amon, L.M.; Fink, D.; Titolo, S.; Welchner, E.; Yoakim, C.; Archambault, J.; White, P.W. Crystal structure of the E2 transactivation domain of human papillomavirus type 11 bound to a protein interaction inhibitor. J. Biol. Chem., 2004, 279, 6976-6985.
190. White, P.W.; Titolo, S.; Brault, K.; Thauvette, L.; Pelletier, A.; Welchner, E.; Bourgon, L.; Doyon, L.; Ogilvie, W.W.; Yoakim, C.; Cordingley, M.G.; Archambault, J. Inhibition of human papillomavirus DNA replication by small molecule antagonists of the E1-E2 protein interaction. J. Biol. Chem., 2003, 278, 26765-26772.
191. Kilby, J.M.; Hopkins, S.; Venetta, T.M.; DiMassimo, B.; Cloud, G.A.; Lee, J.Y.; Alldredge, L.; Hunter, E.; Lambert, D.; Bolognesi, D.; Mathews, T.; Johnson, M.R.; Nowak, M.A.; Shaw, G.M.; Saag, M.S. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nat. Med., 1998, 4, 1302-1307.
192. Busschots, K.; De Rijck, J.; Christ, F.; Debyser, Z. In search of small molecules blocking interactions between HIV proteins and intracellular cofactors. Mol. Biosyst., 2009, 5, 21-31.
193. Dorr, P.; Westby, M.; Dobbs, S.; Griffin, P.; Irvine, B.; Macartney, M.; Mori, J.; Rickett, G.; Smith-Burchnell, C.; Napier, C.; Webster, R.; Armour, D.; Price, D.; Stammen, B.; Wood, A.; Perros, M. Maraviroc (UK-427857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob. Agents Chemother., 2005, 49, 4721-4732.
194. Strizki, J.M.; Tremblay, C.; Xu, S.; Wojcik, L.; Wagner, N.; Gonsiorek, W.; Hipkin, R.W.; Chou, C.-C.; Pugliese-Sivo, C.; Xiao, Y.; Tagat, J.R.; Cox, K.; Priestley, T.; Sorota, S.; Huang, W.; Hirsch, M.; Reyes, G.R.; Baroudy, B.M. Discovery and characterization of vicriviroc (SCH 417690), a CCR5 antagonist with potent activity against human immunodeficiency virus type 1. Antimicrob. Agents Chemother., 2005, 49, 4911-4919.
195. Kondru, R.; Zhang, J.; Ji, C.; Mirzadegan, T.; Rotstein, D.; Sankuratri, S.; Dioszegi, M. Molecular interactions of CCR5 with major classes of small-molecule anti-HIV CCR5 antagonists. Mol. Pharmacol., 2008, 73, 789-800.
196. Mansfield, R.; Able, S.; Griffin, P.; Irvine, B.; James, I.; Macartney, M.; Miller, K.; Mills, J.; Napier, C.; Navratilova, I.; Perros, M.; Rickett, G.; Root, H.; van der Ryst, E.; Westby, M.; Dorr, P. CCR5 pharmacology methodologies and associated applications. Chemokines, Pt A, 2009, 460, 17-+.
197. Dorr, P.; Perros, M. CCR5 inhibitors in HIV-1 therapy. Expert Opin. Drug Discov., 2008, 3, 1345-1361.
198. Madani, N.; Schon, A.; Princiotto, A.M.; LaLonde, J.M.; Courter, J.R.; Soeta, T.; Ng, D.; Wang, L.P.; Brower, E.T.; Xiang, S.H.; Do Kwon, Y.; Huang, C.C.; Wyatt, R.; Kwong, P.D.; Freire, E.; Smith, A.B.; Sodroski, J. Small-molecule CD4 mimics interact with a highly conserved pocket on HIV-1 gp120. Structure, 2008, 16, 1689-1701.
199. Schon, A.; Madani, N.; Klein, J.C.; Hubicki, A.; Ng, D.; Yang, X.; Smith, A.B.; Sodroski, J.; Freire, E. Thermodynamics of binding of a low-molecular-weight CD4 mimetic to HIV-1 gp120. Biochemistry, 2006, 45, 10973-10980.
200. Zhao, Q.; Ma, L.Y.; Jiang, S.B.; Lu, H.; Liu, S.W.; He, Y.X.; Strick, N.; Neamati, N.; Debnath, A.K. N-phenyl-N'-(2,2,6,6-tetramethyl-piperidin-4-yl)-oxalamides as a new class of HIV-1 entry inhibitors that prevent gp120 binding to CD4. Virology, 2005, 339, 213-225.